Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-7429 in Advanced Solid Tumors
NCT07787208Phase 1Recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Jun 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ONO-7429 in solid tumor, sponsored by Ono Pharmaceutical. Primary endpoints: Dose-limiting toxicities at 21 days and Adverse event at 6 months. Started Jun 2026; status: recruiting.
02
Drugs
ONO-7429
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07787208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07787208.